[ad_1]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $34.00.
Several equities research analysts have recently weighed in on KPTI shares. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 16th. Robert W. Baird dropped their target price on Karyopharm Therapeutics from $42.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th.
Read Our Latest Research Report on Karyopharm Therapeutics
Karyopharm Therapeutics Price Performance
Shares of KPTI stock opened at $6.08 on Monday. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $16.95. The stock’s 50 day simple moving average is $5.34 and its two-hundred day simple moving average is $5.20. The company has a market cap of $52.71 million, a PE ratio of -0.42 and a beta of 0.35.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The firm had revenue of $37.93 million during the quarter, compared to analysts’ expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.
Institutional Trading of Karyopharm Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth $45,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth $56,000. Silverback Asset Management LLC boosted its position in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after purchasing an additional 20,000 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth $163,000. Institutional investors own 66.44% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Further Reading
Receive News & Ratings for Karyopharm Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Karyopharm Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link